Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSV vaccine response study in older adults
ACTRN12625001211459Phase 4Not yet recruiting
- Sponsor
- Tasmanian Health Service
- Start
- Jan 2026
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in respiratory syncytial virus disease (RSV) comparing Arexvy arm with Abrysvo comparator arm (2 arms). Primary endpoints: Change in antibody response and Change in T cell response. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
GSK3003899ARSVpreF vaccine
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on ACTRN12625001211459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625001211459.